DEL MAR, Calif.--(BUSINESS WIRE)--Jun 12, 2024-- SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced the U.S.
commercial launch of its novel BowTie Sacroiliac Fusion System. BowTie is the first SI fusion technology to be based on long-standing, validated joint fusion principles established by the AO foundation and is now the lone commercially available device that integrates both intra‐articular and transfixing components. Pierce Nunley, MD, Director of the Spine Institute of Louisiana, performed the first domestic surgery on June 11 th at The Spine Center of Excellence in Shreveport, Louisiana.
This press release features multimedia. View the full release here: https://www.businesswire.
com/news/home/20240612941517/en/ BowTie first U.S. implantation Pierce Nunley, MD 6-11-24 (Photo: Business Wire) The MIS BowTie technology and its posterior-inferior surgical technique achieve the AO-based principles of minimal tissue disruption, thorough joint preparation, and rigid fixation to enable true and robust arthrodesis.
The device features a novel bowtie shape as well as integrated transfixation and iliac screws to maximize rigidity. It also utilizes a proprietary porous structure and roughened surface technology to facilitate osteointegration. Today’s first domestic surgery is part of a limited commercial release that will be expanded in the coming mo.
